Form D · Biotechnology

AesRx, LLC

Newton, MA · CIK 0001521095

Offering snapshot reported Dec 10, 2013 · SEC filing

Reported sold
$600K
Offering amount: $750K
Investors reported
18
Form D · investor count
Minimum accepted
$3.22K
Reported outside-investor minimum
First sale
Nov 25, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 10, 2013Initial$600,000No comparison18SEC filing
May 9, 2013Amendment$1,355,150$75,000vs Apr 9, 201322SEC filing
Apr 9, 2013Amendment$1,280,150$321,650vs Dec 20, 201220SEC filing
Dec 20, 2012Amendment$958,500$408,500vs Oct 9, 201219SEC filing
Oct 9, 2012Amendment$550,000$25,000vs Sep 10, 201212SEC filing
Sep 10, 2012Initial$525,000No comparison11SEC filing
Jun 30, 2011Amendment$1,505,000$130,000vs May 20, 20118SEC filing
May 20, 2011Initial$1,375,000No comparison2SEC filing

Offering details

Securities
Debt, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-207703

Source: Form D, filed Dec 10, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
R. John Fletcher Director
Colin Hill Director
Maggie Le Flore Director
Mary K. Pendergast Director
Stephen R. Seiler Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
275 Grove Street Suite 2 400
Newton, MA, 02466